NovoCure
NVCR
NVCR
293 hedge funds and large institutions have $5.38B invested in NovoCure in 2023 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 85 increasing their positions, 97 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
12% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 97
13% less capital invested
Capital invested by funds: $6.2B → $5.38B (-$824M)
15% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 53
Holders
293
Holding in Top 10
3
Calls
$151M
Puts
$57.8M
Top Buyers
| 1 | +$92.2M | |
| 2 | +$70.7M | |
| 3 | +$43.3M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$32.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.3M |
Top Sellers
| 1 | -$18.5M | |
| 2 | -$18.2M | |
| 3 | -$15.7M | |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$8.02M |
| 5 |
Goldman Sachs
New York
|
-$7.22M |